+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cryptococcosis Treatment Market - Global Forecast 2026-2032- Product Image
Cryptococcosis Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Cryptococcosis Treatment Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5012985
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cryptococcosis Treatment Market is projected to reach USD 6.31 Billion in 2026. It is expected to continue growing at a CAGR of 7.88%, reaching USD 9.97 Billion by 2032.

Cryptococcosis treatment remains a high-priority antifungal market because cryptococcal meningitis is a leading cause of death among people with advanced HIV disease and an important opportunistic infection in transplant recipients and other immunocompromised patients. Published global burden estimates have placed cryptococcal meningitis at roughly 152,000 annual cases and 112,000 deaths among people with HIV, underscoring a persistent need for faster diagnosis, safer induction therapy, and reliable access to essential antifungal drugs.

For pharmaceutical and antifungal therapy vendors, market opportunity is shaped by guideline-driven care pathways. Standard cryptococcosis treatment depends on induction, consolidation, and maintenance therapy using amphotericin B formulations, flucytosine, and fluconazole, with the World Health Organization endorsing simplified liposomal amphotericin B-based regimens where feasible. Competitive advantage will come from improving tolerability, expanding supply of flucytosine and liposomal amphotericin B, supporting antifungal stewardship, and aligning access programs with high-burden settings.

Transformative Shifts in the Treatment Landscape

The cryptococcosis treatment landscape is shifting from prolonged, toxicity-prone inpatient regimens toward shorter, evidence-based induction approaches that can improve adherence and reduce hospital burden. The AMBITION-cm trial demonstrated that a single high dose of liposomal amphotericin B, combined with flucytosine and fluconazole, was non-inferior to the traditional 7-day amphotericin B deoxycholate regimen for HIV-associated cryptococcal meningitis and had fewer serious adverse events, influencing global cryptococcal meningitis treatment strategies.

At the same time, demand is being reshaped by earlier cryptococcal antigen screening among people with advanced HIV, expanded transplant programs, and greater recognition of non-HIV cryptococcosis. The market is also moving toward integrated antifungal supply planning, because treatment outcomes depend not only on drug efficacy but also on diagnostic confirmation, lumbar puncture capacity, management of raised intracranial pressure, renal and hematologic monitoring, and long-term fluconazole maintenance therapy.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence cryptococcosis treatment through earlier risk identification, optimized clinical workflows, and better forecasting of antifungal demand. AI-enabled electronic health record models can flag patients with advanced HIV, low CD4 counts, transplant immunosuppression, hematologic malignancy, prolonged corticosteroid exposure, or persistent neurologic symptoms for cryptococcal antigen testing and urgent evaluation. These tools can support earlier intervention, although they require clinical validation, governance, data privacy safeguards, and bias monitoring before broad deployment.

For pharmaceutical partners, AI can strengthen pharmacovigilance, supply chain resilience, and clinical development. Machine learning can help detect adverse event patterns linked to amphotericin B nephrotoxicity or flucytosine-related cytopenias, forecast regional demand for liposomal amphotericin B and fluconazole, and identify trial sites with high unmet need. Generative and predictive models may also accelerate antifungal discovery, but regulatory-grade evidence, transparent datasets, and stewardship safeguards remain essential.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific presents a mixed profile, with advanced treatment infrastructure in Japan, Australia, and South Korea and substantial unmet need in India and parts of Southeast Asia where advanced HIV disease, delayed diagnosis, and laboratory access gaps remain important. India’s large HIV treatment network, expanding tertiary care base, and rising number of immunocompromised patients make access to cryptococcal antigen testing, amphotericin B formulations, flucytosine, and fluconazole central to improving outcomes. North America benefits from strong infectious disease networks, transplant medicine, advanced diagnostics, and access to liposomal amphotericin B, while care is increasingly focused on rapid diagnosis and management of immunocompromised populations beyond HIV, including solid organ transplant, oncology, and biologic therapy patients.

Latin America has meaningful demand across Brazil and Mexico, where HIV programs and tertiary care hospitals support diagnosis but access to flucytosine and liposomal amphotericin B can be uneven across public and private settings. Europe is characterized by guideline-led treatment, robust hospital systems, reimbursement pathways, and specialized infectious disease care, although migration, oncology, intensive care, and transplant populations sustain clinical need for cryptococcosis treatment and long-term antifungal monitoring.

The Middle East is influenced by expanding tertiary care, transplant services, and GCC health investment, creating demand for hospital-based protocols and premium antifungal formulations. Africa remains the highest-burden region for HIV-associated cryptococcal meningitis, with public health agencies consistently identifying cryptococcal disease as a major cause of mortality among people with advanced HIV. In African markets, the greatest treatment gains are linked to cryptococcal antigen screening, reliable amphotericin and flucytosine availability, lumbar puncture services, electrolyte and renal monitoring, and implementation of WHO-recommended cryptococcosis treatment regimens.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

Within ASEAN, cryptococcosis treatment demand is linked to HIV program maturity, laboratory access, referral pathways, and antifungal procurement capacity, with urban referral centers often better equipped than rural facilities to deliver induction therapy and monitor amphotericin-related toxicity. The GCC is advancing specialized infectious disease, oncology, and transplant care, creating demand for premium antifungal formulations, hospital-based treatment protocols, and integrated diagnostics across high-acuity medical centers.

The European Union supports a mature treatment environment through harmonized regulatory standards, antimicrobial stewardship, strong hospital systems, and clinical guideline adoption, while BRICS markets are pivotal because they combine large patient populations, expanding healthcare infrastructure, high HIV or immunocompromised patient volumes in several member countries, and persistent access gaps. G7 countries generally lead in diagnostic availability, clinical trial capacity, pharmacovigilance, and reimbursement for liposomal amphotericin B, supporting adoption of evidence-based cryptococcal meningitis therapy and short-course induction approaches.

NATO member markets overlap significantly with high-income health systems that maintain hospital readiness, infectious disease expertise, and coordinated medical supply planning, although access and reimbursement still vary by country. Across ASEAN, GCC, the European Union, BRICS, G7, and NATO, the defining commercial issue is not only clinical need but also whether procurement, reimbursement, guideline implementation, and specialist capacity ensure consistent access to amphotericin B, flucytosine, and fluconazole.

Key Country Insights Across Major Cryptococcosis Treatment Markets

The United States and Canada represent high-value cryptococcosis treatment markets driven by advanced HIV care, transplant medicine, oncology, biologic immunosuppression, rapid diagnostics, and access to infectious disease specialists, with continued emphasis on toxicity management and real-world safety monitoring. Mexico and Brazil show expanding need supported by large public health systems and HIV care networks, but differences in regional procurement, hospital referral access, flucytosine availability, and specialist coverage can affect consistency in cryptococcal meningitis therapy.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from strong hospital systems, reimbursement frameworks, microbiology capacity, and guideline-based antifungal use, while Russia presents demand shaped by HIV burden, tertiary care capacity, regional healthcare variation, and procurement variability. China and India are central to Asia-Pacific demand because of large patient bases, expanding diagnostic infrastructure, growing transplant and oncology services, and rising immunocompromised populations, although access to flucytosine and liposomal amphotericin B remains an important determinant of outcomes.

Japan, Australia, and South Korea are advanced markets with high standards for hospital care, diagnostics, intensive monitoring, and antifungal safety oversight. These countries are positioned to adopt optimized cryptococcosis treatment regimens, real-world evidence programs, pharmacovigilance systems, and AI-enabled clinical decision support while maintaining strong expectations for clinical validation and stewardship.

Actionable Recommendations for Antifungal Industry Leaders

Industry vendors should prioritize reliable access to WHO-aligned antifungal regimens, especially liposomal amphotericin B, flucytosine, and fluconazole, while supporting local procurement models in high-burden countries. Organizations can differentiate by pairing drug supply with clinical education on induction therapy, renal monitoring, electrolyte replacement, cytopenia monitoring, therapeutic sequencing, lumbar puncture access, and management of raised intracranial pressure.

Strategic investment should focus on evidence generation, including real-world outcomes for short-course liposomal amphotericin B regimens, safety monitoring in diverse populations, and implementation research in resource-constrained settings. Partnerships with HIV programs, transplant centers, diagnostic manufacturers, public health agencies, and ministries of health can expand screening-to-treatment pathways, strengthen antifungal stewardship, and reduce preventable cryptococcal meningitis mortality.

Research Methodology

This executive summary is based on triangulation of peer-reviewed clinical evidence, international treatment guidelines, public health burden estimates, regulatory knowledge, and established infectious disease practice standards. Key reference points include WHO guidance for advanced HIV disease and cryptococcal disease, clinical trial evidence supporting liposomal amphotericin B-based induction therapy, and widely recognized treatment principles involving amphotericin B, flucytosine, and fluconazole.

The analysis applies a market-oriented lens to clinical data, evaluating disease burden, treatment access, regional health infrastructure, procurement dynamics, reimbursement factors, specialist availability, diagnostic readiness, and adoption barriers. Insights are structured to support SEO relevance for cryptococcosis treatment, cryptococcal meningitis therapy, antifungal drugs, amphotericin B, liposomal amphotericin B, flucytosine, fluconazole, cryptococcal antigen screening, and opportunistic infection management.

Conclusion

The cryptococcosis treatment market is entering a more evidence-driven phase as shorter liposomal amphotericin B regimens, cryptococcal antigen screening, and integrated HIV care reshape treatment expectations. Despite advances, preventable mortality remains high where diagnostics, flucytosine, amphotericin formulations, lumbar puncture services, and skilled clinical management are limited.

Pharmaceutical and antifungal therapy vendors that combine clinically proven therapies with access strategies, pharmacovigilance, stewardship, and implementation partnerships will be best positioned to address unmet need. The strongest opportunities will come from aligning innovation with practical delivery in high-burden regions and specialized immunocompromised care settings.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cryptococcosis Treatment Market, by Drug Class
7.1. Introduction
7.2. Azoles
7.2.1. Fluconazole
7.2.2. Posaconazole
7.2.3. Voriconazole
7.3. Flucytosine
7.4. Polyenes
7.4.1. Amphotericin B Deoxycholate
7.4.2. Liposomal Amphotericin B
8. Cryptococcosis Treatment Market, by Administration Route
8.1. Introduction
8.2. Intravenous
8.2.1. Central Line
8.2.2. Peripheral
8.3. Oral
8.3.1. Suspension
8.3.2. Tablet
9. Cryptococcosis Treatment Market, by Patient Type
9.1. Introduction
9.2. HIV Infected
9.3. Non-HIV Infected
9.3.1. Immunocompetent
9.3.2. Transplant Patients
10. Cryptococcosis Treatment Market, by Therapy Phase
10.1. Introduction
10.2. Induction Therapy
10.3. Consolidation Therapy
10.4. Maintenance Therapy
11. Cryptococcosis Treatment Market, by End User
11.1. Introduction
11.2. Clinics
11.2.1. Outpatient Clinics
11.2.2. Specialist Clinics
11.3. Home Care
11.4. Hospitals
12. Cryptococcosis Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. Cryptococcosis Treatment Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Cryptococcosis Treatment Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Cryptococcosis Treatment Market, by Country
15.1. China
15.2. United States
15.3. India
15.4. Japan
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. South Korea
15.9. France
15.10. Canada
15.11. Italy
15.12. Brazil
15.13. Mexico
15.14. Russia
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Astellas Pharma Inc.
17.2. Aurobindo Pharma Limited
17.3. Bausch Health Companies Inc.
17.4. Cipla Limited
17.5. Dr. Reddy's Laboratories Limited
17.6. Gilead Sciences, Inc.
17.7. Lupin Limited
17.8. Pfizer Inc.
17.9. Sun Pharmaceutical Industries Limited
17.10. Teva Pharmaceutical Industries Ltd.
17.11. Viatris Inc.
17.12. Xellia Pharmaceuticals ApS
17.13. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL AZOLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL AZOLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL AZOLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL FLUCONAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL FLUCONAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL FLUCONAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL POSACONAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL POSACONAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL POSACONAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL VORICONAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL VORICONAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL VORICONAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL FLUCYTOSINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL FLUCYTOSINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL FLUCYTOSINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL POLYENES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL POLYENES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL POLYENES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL AMPHOTERICIN B DEOXYCHOLATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL AMPHOTERICIN B DEOXYCHOLATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL AMPHOTERICIN B DEOXYCHOLATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL LIPOSOMAL AMPHOTERICIN B MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL LIPOSOMAL AMPHOTERICIN B MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL LIPOSOMAL AMPHOTERICIN B MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CENTRAL LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CENTRAL LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CENTRAL LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL PERIPHERAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL PERIPHERAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL PERIPHERAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SUSPENSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SUSPENSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SUSPENSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL HIV INFECTED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL HIV INFECTED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL HIV INFECTED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL NON-HIV INFECTED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL NON-HIV INFECTED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL NON-HIV INFECTED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL IMMUNOCOMPETENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL IMMUNOCOMPETENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL IMMUNOCOMPETENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL TRANSPLANT PATIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL TRANSPLANT PATIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL TRANSPLANT PATIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL INDUCTION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL INDUCTION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL INDUCTION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CONSOLIDATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CONSOLIDATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CONSOLIDATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL SPECIALIST CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL SPECIALIST CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SPECIALIST CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 107. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 109. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 110. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 111. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 112. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 113. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 114. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 115. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 116. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 117. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 118. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 119. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 127. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 128. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 129. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 130. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 131. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 136. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 137. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 138. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 139. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 140. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 141. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 142. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 143. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 146. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 148. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 149. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 150. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 151. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 152. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 153. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 154. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 155. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 156. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 157. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 158. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 159. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 161. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 162. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 163. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 164. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 165. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 166. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 167. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 168. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 169. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 170. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 173. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 174. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 175. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 176. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 177. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 178. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 179. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 180. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 181. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 182. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 183. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 184. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 185. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 186. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 187. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 188. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 189. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 190. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 191. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 192. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 193. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 194. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 195. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 196. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 197. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 198. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 199. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 200. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 201. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 202. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 203. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 204. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 205. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 206. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 207. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 208. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 209. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 210. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 211. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 225. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 226. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 227. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 228. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 229. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 230. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 231. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 232. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 233. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 234. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 235. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 237. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 238. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 239. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 240. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 241. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 242. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 243. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 244. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 245. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 246. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 247. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 248. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 250. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 251. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 252. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 253. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 254. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 255. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 256. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 257. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 258. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 259. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 260. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 261. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 262. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 264. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 265. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 266. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 267. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 268. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 269. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 270. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 271. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 272. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 273. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 274. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 275. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 276. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 277. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 278. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 280. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 281. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 282. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 283. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 284. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 285. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 286. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 287. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 288. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 290. INDIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 291. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 292. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 293. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 294. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 295. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 296. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 297. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 298. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 299. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 300. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 301. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 302. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 303. JAPAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 304. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 305. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 306. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 307. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 308. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 309. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 310. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 311. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 312. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 313. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 314. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 315. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 316. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 317. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 318. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 319. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 320. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 321. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 322. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 323. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 324. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 325. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 326. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 327. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 328. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 329. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 330. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 331. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 332. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 333. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 334. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 335. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 336. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 337. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 338. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 339. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 340. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 341. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 342. AUSTRALIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 343. SOUTH KOREA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 344. SOUTH KOREA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 345. SOUTH KOREA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2017-2032 (USD MILLION)
TABLE 346. SOUTH KOREA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2017-2032 (USD MILLION)
TABLE 347. SOUTH KOREA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 348. SOUTH KOREA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2017-2032 (USD MILLION)
TABLE 349. SOUTH KOREA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 350. SOUTH KOREA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 351. SOUTH KOREA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2017-2032 (USD MILLION)
TABLE 352. SOUTH KOREA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY THERAPY PHASE, 2017-2032 (USD MILLION)
TABLE 353. SOUTH KOREA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER,

Companies Mentioned

  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Gilead Sciences, Inc.
  • Lupin Limited
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Xellia Pharmaceuticals ApS
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 6.31 Billion
Forecasted Market Value ( USD ) by 2032 $ 9.97 Billion
Compound Annual Growth Rate7.8%
Regions CoveredGlobal
No. of Companies Mentioned13

Related Topics

Related Reports

Cryptococcosis Market - Global Forecast 2026-2032 - Product Image

Cryptococcosis Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Cryptococcosis Therapeutics - Global Strategic Business Report - Product Image

Cryptococcosis Therapeutics - Global Strategic Business Report

  • Report
  • 473 Pages
  • Global
From
Cryptococcosis Therapeutics Market Report 2026 - Product Image

Cryptococcosis Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Cryptococcosis Treatment - Global Strategic Business Report - Product Image

Cryptococcosis Treatment - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Cryptococcosis Therapeutics Market - Forecast from 2026 to 2031 - Product Image

Cryptococcosis Therapeutics Market - Forecast from 2026 to 2031

  • Report
  • 141 Pages
  • Global
From

About the Cryptococcosis Drug Market

Cryptococcosis is a fungal infection caused by the Cryptococcus neoformans and Cryptococcus gattii species. It is a serious infection that can affect the lungs, central nervous system, and other organs. Treatment of cryptococcosis typically involves antifungal medications, such as amphotericin B, fluconazole, and voriconazole. These drugs are used to treat both cryptococcal meningitis and cryptococcal pneumonia. The cryptococcosis drug market is a subset of the infectious diseases drug market. It is composed of antifungal medications used to treat cryptococcosis. These drugs are used to treat both cryptococcal meningitis and cryptococcal pneumonia. Some companies in the cryptococcosis drug market include Pfizer, Merck, GlaxoSmithKline, AstraZeneca, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.